Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) RatMine GViewer (Genome Viewer) Overgo Probe Designer VCMap
Aging & Age-Related Disease Cancer Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
PhenoMiner Database Result        View data table  |  Download data table  |  View compact data table        

Generate Chart For    
    (Chart displayed below)
Rat Strains
{{sample.term}}
Measurement Methods
{{method.term}}
Age
{{ageRange}}
Experimental Conditions
     {{ cond }}

Minimum Value:    Maximum Value:    Sex:


 
Options:  View chart  |  Download data table  |  View compact data table
Study IDStudyExperiment NameExperiment NotesStrain Ont IDStrainSexAge# of AnimalsSample NotesClinical Measurement Ont IDPhenotypeFormulaClinical Measurement NotesAverage TypeValueUnitsSEMSDMethod Ont IDMethodMethod SiteMethod DurationMethod NotesPost Insult TypePost Insult Time ValuePost Insult Time UnitConditionsRecord IDCondition 1Condition 2
76Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601mammary gland integrity traitRS:0000032ACI/SegHsdfemale203 days to 201 days11CMO:0000948percentage of study population developing mammary tumors during a period of time0%MMO:0000158manual palpation methodmammary gland0bilateral ovariectomy then 17 beta-estradiol (27.5 mg) (for 140 days)11379bilateral ovariectomy17 beta-estradiol (27.5 mg) (for 140 days)
76Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601mammary gland integrity traitRS:0000032ACI/SegHsdfemale518 days to 201 days3CMO:0000948percentage of study population developing mammary tumors during a period of time0%MMO:0000158manual palpation methodmammary gland0control condition11378control condition
86Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45mammary gland integrity traitRS:0000809SS-Chr 9BN/Mcwifemale162 days to 152 days40CMO:0000948percentage of study population developing mammary tumors during a period of time93%MMO:0000158manual palpation method0200 mg DMBA in 10 ml seame oilDMBA oral gavage105days7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)114957,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
86Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45mammary gland integrity traitRS:0000806SS-Chr 6BN/Mcwifemale162 days to 152 days20CMO:0000948percentage of study population developing mammary tumors during a period of time20%MMO:0000158manual palpation method0200 mg DMBA in 10 ml seame oilDMBA oral gavage105days7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)114947,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
86Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45mammary gland integrity traitRS:0000805SS-Chr 5BN/Mcwifemale162 days to 152 days13CMO:0000948percentage of study population developing mammary tumors during a period of time54%MMO:0000158manual palpation method0200 mg DMBA in 10 ml seame oilDMBA oral gavage105days7,12-dimethyltetraphene (DMBA) (65 g/kg) (for 105 days)114937,12-dimethyltetraphene (DMBA) (65 g/kg) (for 105 days)
144Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30mammary gland integrity traitRS:0000032ACI/SegHsdfemale264 days to 206 days31CMO:0000948percentage of study population developing mammary tumors during a period of timemean100%MMO:0000158manual palpation method017 beta-estradiol (27.5 mg) (between 147 and 195 days)6611217 beta-estradiol (27.5 mg) (between 147 and 195 days)
144Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30mammary gland integrity traitRS:0000186COP/OlaHsdfemale330 days to 212 days7CMO:0000948percentage of study population developing mammary tumors during a period of timemean43.8%MMO:0000158manual palpation method017 beta-estradiol (27.5 mg) (between 212 and 330 days)6611317 beta-estradiol (27.5 mg) (between 212 and 330 days)
76Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601mammary gland integrity traitRS:0000032ACI/SegHsdfemale260 days to 160 days21CMO:0000948percentage of study population developing mammary tumors during a period of time100%MMO:0000158manual palpation methodmammary gland017 beta-estradiol (27.5 mg) (for 197 days)6554917 beta-estradiol (27.5 mg) (for 197 days)
86Adamovic T, et al., Genes Chromosomes Cancer. 2010 Nov;49(11):1035-45mammary gland integrity traitRS:0000803SS-Chr 3BN/Mcwifemale162 days to 152 days14CMO:0000948percentage of study population developing mammary tumors during a period of time29%MMO:0000158manual palpation method0200 mg DMBA in 10 ml seame oilDMBA oral gavage105days7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)655667,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
81Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800mammary gland integrity traitRS:0000032ACI/SegHsdfemale259 days to 143 days22CMO:0000948percentage of study population developing mammary tumors during a period of time94%MMO:0000158manual palpation method0crystalline implant17 beta-estradiol (27.5 mg) (between 193 and 199 days)6576417 beta-estradiol (27.5 mg) (between 193 and 199 days)
81Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800mammary gland integrity traitRS:0000155BN/SsNHsdfemale259 days13CMO:0000948percentage of study population developing mammary tumors during a period of time0%MMO:0000158manual palpation method0crystalline implant17 beta-estradiol (27.5 mg) (between 196 and 199 days)6576517 beta-estradiol (27.5 mg) (between 196 and 199 days)

Contact Us |  About Us |  Jobs at RGD